Slide 1: Investor Presentation cover letter to NSE
INVICTA DIAGNOSTIC LIMITED CIN: L86100MH2023PLC414723 Registered Office: 1 Ground Floor, Plot No. 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013. | Email: info@pcdiagnostics.in | Contact: 022 4971 0036 May 22nd, 2026 National Stock Exchange of India Limited Exchange Plaza, 5th F
Slide 2: Invicta Diagnostic Limited Investor Presentation
Invicta Diagnostic Limited Investor Presentation Investor Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the Presentation), which have been prepared by Invicta Diagnostic Limited (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not f
Slide 4: Why Invicta Diagnostic Limited
Why Invicta Diagnostic Limited Strong presence in a high-growth diagnostics market Operates in the Mumbai Metropolitan Region, one of India’s largest and fastest-growing urban healthcare markets, with increasing demand for advanced diagnostics. Radiology-led business with high entry barriers Focus o
Slide 5: About Invicta Diagnostic Limited
About Invicta Diagnostic Limited Invicta Diagnostic Limited is a diagnostic services company operating across the Mumbai Metropolitan Region under the consumer brand PC Diagnostics, offering integrated radiology and pathology services. The Company provides a comprehensive diagnostic portfolio across
Slide 6: Key Facts & Figures
Key Facts & Figures Integrated Diagnostics Network ~91.40% 220+ 8 540+ 155+ Radiology Revenue Radiology Tests Diagnostic Centres Pathology Tests Team Size Contribution FY26 Financial & Operational Highlights ₹3,272 1.56 ₹2,092 98,867 1,54,675 Per Patient Revenue Tests Per Patient Average Revenue Pat
Slide 7: Invicta Diagnostic Limited's – Growth Journey
Invicta Diagnostic Limited’s – Growth Journey 2023 | Corporate Transition & Network Expansion 2025 | Platform Consolidation • Converted from LLP to Invicta Diagnostic Private Limited • Acquired Porteus Medical LLP as subsidiary • Acquired PCD Diagnostics LLP (Marol, Andheri East) as • Acquired Prima
Slide 8: Board Of Directors
Board Of Directors Dr. Sanket Vinod Jain Dr. Ketan Jayantilal Jain Mr. Rohit Prakash Srivastava Mr. Aayush Kamleshbhai Shah Ms. Shilpa Ajay Bhatia Chairman & Non-Executive Non-Executive Director Chief Financial Officer Independent Director Independent Director Director & Whole Time Director Consulta
Slide 9: Business Model Overview
Business Model Overview Integrated, radiology-focused diagnostics platform with scalable urban expansion. Demand Generation Collection & Service Network Processing Backbone Spoke Centres • Central lab for routine pathology testing • Outsourced reference labs for specialised • Local patient touchpoin
Slide 10: Core Diagnostic Services
Core Diagnostic Services Radiology Pathology Revenue From Radiology Test (In ₹ Cr) Revenue from pathology Tests (In ₹ Cr) • Routine biochemistry and clinical • X-rays, ultrasound and ECG to 2.90 pathology to specialised and molecular 27.19 29.57 advanced imaging such as CT, MRI 2.78 diagnostics and
Slide 11: Diagnostic Services & Customer Base
Diagnostic Services & Customer Base Basic Radiology Advanced Radiology Routine Pathology Testing Specialised Pathology Testing • 45+ X-ray studies including • CT scans for trauma, cancer, and • In-house testing for • Advanced biochemistry and chest, bone, abdominal, and musculoskeletal disorders. bi
Slide 12: Key Consolidated Operational Metrics
Key Consolidated Operational Metrics Number of diagnostic centres Number of patients served Number of tests performed 103,602 176,248 8 8 98,867 7 154,675 42,129 73,372 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Number of tests per patient visit Individual Consumer Business Revenue (₹ in Cr) Avera
Slide 13: Hub-and-Spoke Operating Model
Hub-and-Spoke Operating Model Spoke Centres (Pathology sample collection + Basic radiology) • Performs routine pathology tests (biochemistry, haematology, clinical pathology) in-house. Customers Hub Centres Centralised • Complex and specialised • Walk-in patients (Basic + Advanced radiology | / Refe
Slide 14: Operational Footprint Across MMR
Operational Footprint Across MMR Self Bhayander East Thane, Sewri, Parel. Thane Centralized Laboratory is Co-located with one of the West Kalwa spoke centre at Parel. Marol Subsidary PCD Diagnostics LLP has its centre at Marol. Dadar Parel Invicta Medical LLP has its centre at Kalwa. Sewri Primacare
Slide 15: Strength
Strength Radiology-Led, High-Entry-Barrier Business Technology-Enabled Operations Strong focus on advanced imaging (MRI, CT, PET-CT) drives higher Robust use of LIMS, RIS-PACS, and ERP systems ensures accuracy, faster realisations and creates significant barriers to entry. turnaround times, and oper
Slide 16: Future Direction
Future Direction Disciplined expansion anchored in radiology leadership, capital efficiency, and regional scale. Growth Execution Strategy • Expansion through organic Capital & Financial centre additions and selective Discipline acquisitions. • Focus on operational or near- • IPO proceeds earmarked
Slide 17: Diagnostic Industry in Maharashtra
Diagnostic Industry in Maharashtra Diagnostic Industry in Maharashtra (In ₹ Bn) Key Growth Factors 72.7 35.45 Maharashtra's radiology segment is fueled by Maharashtra's population is projected to grow 24.7 rising chronic disease cases, increased from 128.1 million in 2024 to 136.8 million by imaging
Slide 18: Competitive Landscape – Diagnostics Sector
Competitive Landscape – Diagnostics Sector Invicta Diagnostic Limited Vijaya Diagnostic Centre Suraksha Diagnostic Limited Metric Krsnaa Diagnostics Limited (#) (*) Limited (*) (#) Revenue (₹ Cr) ₹ 32.35 ₹ 814.20 ₹ 399 ₹ 153.10 EBITDA (₹ Cr) ₹ 10.45 ₹ 336.90 ₹ 110.60 ₹ 49.62 EBITDA Margin (%) 31.63%
Slide 19: Profit & Loss Statement H2 & FY26
Profit & Loss Statement H2 & FY26 (₹ In Cr except EPS) Particulars H2 FY26 FY26 Revenue from operations 15.41 32.35 Other Income 0.56 0.69 Total Income 15.96 33.04 Cost Of Materials Consumed 1.38 2.73 Employee costs 3.16 4.89 Other expenses 7.87 14.97 Total Expenses 12.41 22.59 EBITDA 3.55 10.45 Fin
Slide 20: Management Comment On FY26 Performance
Management Comment On FY26 Performance FY26 has been a landmark year for Invicta Diagnostic Limited as we successfully completed our NSE Emerge listing in December 2025 and concluded the year with a stable financial and operational performance. During FY26, we reported Total Income of ₹33.04 Cr and
Slide 21: Financial Highlights
Financial Highlights ROE ROCE 9.76% 13.44% Current Receivable Ratio Turnover Financial Takeaways • Strong revenue growth driven by network expansion, higher patient volumes, 4.79 Times 57 Days and a radiology-led service mix. • High realisations and margins supported by advanced imaging (MRI, CT, PE
Slide 22: Key Consolidated Financial Highlights
Key Consolidated Financial Highlights Total Income (In ₹ Cr) EBITDA (In ₹ Cr) Net Profit (In ₹ Cr) EBITDA % Net Profit % 33.04 55.00 54.00 53.00 52.00 51.00 30.18 10.45 50.00 49.00 45.00 48.00 47.00 46.00 9.29 45.00 44.00 43.00 42.00 41.00 40.00 39.00 38.00 37.00 36.00 7.15 35.00 34.00 31.63 33.00 3
Slide 23: Consolidated Profit & Loss And Cash Flow Statement
Consolidated Profit & Loss And Cash Flow Statement All Amount ₹ In Cr & Margins In % Particulars FY24 FY25 FY26 Revenues 15.83 30.10 32.35 Other Income 0.07 0.09 0.69 Total Income 15.90 30.18 33.04 Cost Of Materials Consumed 1.12 2.19 2.73 Employee costs 2.14 4.81 4.89 Other Expense 5.49 13.90 14.97
Slide 24: Consolidated Balance Sheet
Consolidated Balance Sheet All Amount In ₹ Cr Equities & Liabilities FY24 FY25 FY26 Assets FY24 FY25 FY26 Equity 0.13 8.42 12.57 Non-Current Assets Reserves 8.54 5.18 37.35 Fixed Assets 19.19 11.73 9.57 Total Equity 8.67 13.60 49.92 Intangible Assets 0.02 0.01 0.01 Non-Current Liabilities Non-Curren
Slide 25: Key Ratios
Key Ratios ROE In % ROCE In % Current Ratio In Times 43.90% 41.84% 39.64% 36.25% 4.79 2.37 13.44% 9.76% 1.62 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Debt to Equity Ratio Receivable Turnover Ratio Earnings Per Share In Times In Days In ₹ 0.44 56.51 5.86 4.90 4.52 0.26 18.52 20.67 0.07 FY24 FY25
Slide 26: Stock Data
Stock Data As On 21-05-2026 As On 31-03-2026 NSE (INVICTA | INE0XJ501010) Share Holding Pattern Share Price (₹) 73.00 33.30% Market Capitalization (₹ Cr) 91.78 Promoter & Promoter Group No. of Shares Outstanding 1,25,71,973 Public Face Value (₹) 10.00 52-week High-Low (₹) 105.00 - 58.10 66.70% Share
Slide 27: Thank You
Thank You Invicta Diagnostic Limited Kirin Advisors Private Limited 217/1 Ambavat Bhawan, Near Janta club, NM 713-B, Lodha Supremus II, Wagle Estate, Joshi Marg, opp. Marathon Futurex, Thane West – 400 604. Mumbai 400013 Phone: 022 4100 2455 Phone: 85916 42582 Website: www.kirinadvisors.com Website: